Trial Profile
EACH: A Randomised Phase II Study Evaluating the Safety and Anti-tumour Activity of the Combination of Avelumab and Cetuximab Relative to Avelumab Monotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EACH
- 22 May 2023 Planned End Date changed from 4 Oct 2022 to 4 Oct 2023.
- 04 Nov 2020 Planned End Date changed from 2 Sep 2022 to 4 Oct 2022.
- 04 Nov 2020 Planned primary completion date changed from 6 Sep 2021 to 4 Oct 2021.